摘要
【目的】:研究CD4 T淋巴细胞内的基础ATP浓度代替CD4/CD 8比值用于评估结核病感染者免疫状态的可行性。【方法】:本研究通过磁珠法分离相同体积全血中的CD4、CD 8细胞,并计算CD4和CD 8细胞的基础ATP浓度来评估结核病感染者的免疫状态,以QFM(Quantiferon Monitor)检测法作为对照。【结果】:研究发现传统的CD4/CD 8比值或CD4 T细胞计数方法不适用于结核病患者。采用CD4细胞的基础ATP浓度来监测活动性结核患者和健康人群,在以290.7×10^(-6)g/L为cut-off值,AUROC为0.8719,其灵敏度为86.21%,特异性为76.19%,差异有统计学意义(P<0.0001)。【结论】:本研究首次使用非外界刺激条件下CD4+T淋巴细胞胞内基础ATP浓度来评估结核病感染者的免疫状态。提示CD4+T淋巴细胞的基础ATP浓度比CD4/CD 8比值可以更好用于评估结核病患者的免疫状态。
【Objective】To investigate the feasibility of basal ATP concentration in CD4 T lymphocytes instead of CD4/CD 8 ratio in assessing the immune status of tuberculosis-infected patients.【Methods】In this study,the CD4 and CD 8 cells in the same volume of whole blood were separated by magnetic beads method,and the basal ATP concentration of CD4 and CD 8 cells was calculated to evaluate the immune status of tuberculosis-infected patients.Quantiferon Monitor(QFM)assay was used as a control.【Results】Our study confirmed that traditional CD4/CD 8 ratio andCD4 T cell counting methodswerenot suitable for TB patients.Using the basal ATP concentration of CD4 cells to monitor active tuberculosis pa⁃tients and healthy people,when the cut-off value was 290.7×10^(-6) g/L,the sensitivity was 86.21%,and the specificity was 76.19%,and the difference was statistically significant(P<0.0001).【Conclussions】In this study,to the best of our knowledge,we have for the first time used the basal ATP concentration in CD4+T lymphocytes to evaluate the immune sta⁃tus of tuberculosis-infected patients under non-external stimulation conditions.It is suggested that the basal ATP concen⁃tration of CD4+T lymphocytes can be better used to evaluate the immune status of tuberculosis patients than CD4/CD 8 ratio.
作者
刘振杰
林东子
涂玉佩
周丹
李玉美
楼建荣
杨翔
徐宁
LIU Zhen-jie;LIN Dong-zi;TU Yu-pei;ZHOU Dan;LI Yu-mei;LOU Jian-rong;YANG Xiang;XU Ning(The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510370,China;Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510370,China;Foshan Fourth People’s Hospital,Foshan 528200,China;Leide Biosciences Co.,Ltd,Guangzhou 510670,China;Dongguan Sixth People's Hospital,Dongguan 523000,China)
出处
《中山大学学报(医学科学版)》
CAS
CSCD
北大核心
2022年第5期748-756,共9页
Journal of Sun Yat-Sen University:Medical Sciences
基金
广州市民政局科技计划项目(2021MZK24)
广东省中医药管理局中医药科研项目(20222058)
广东省珠江人才计划(00201512)
广州开发区创业和创新领军人才(二期)(2021-L033)
羊城创新创业领军人才支持计划(2016011)。